Compare Goldman Sachs Group Inc (GS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Neurocrine Biosciences Inc — how do they compare? Goldman Sachs Group Inc trades at $1,035.36 (market cap $301.19B), while Neurocrine Biosciences Inc trades at $161.12 (market cap $16.46B). The key difference: Goldman Sachs Group Inc is far larger — about 18.3× Neurocrine Biosciences Inc's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| GS | NBIX | |
|---|---|---|
Market Cap | $301.19B | $16.46B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $185.50 |
52-Week Low | $715.95 | $123.10 |
Dividend Yield | 1.93% | — |
Enterprise Value | — | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,034.41, down 0.5% on the day, with a neutral technical signal. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and revenue growth accelerating to $58.3B in 2025. Analyst consensus is mixed with 40% buy ratings but a $1,160 price target suggesting 12% upside potential. Recent news highlights Goldman's leadership role in major upcoming IPOs including Anthropic, SpaceX, and OpenAI.
The outlook remains positive given Goldman's positioning in the upcoming AI IPO wave and strong investment banking pipeline. Key risks include volatile cash flow patterns with negative operating cash flow in recent periods and market sensitivity to interest rate changes. The stock appears reasonably valued at 16x P/E with 31.7% net margins supporting further upside if earnings momentum continues.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
